Open AccessTumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review
Author(s) -
Pengfei Zhu,
Yun-Wang Chen,
Mingxing Wang,
Ya-Ya Deng,
Shuang-Yue Pan,
Zheling Chen,
Liu Yang
Publication year - 2021
Publication title -
anti-cancer drugs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.651
H-Index - 93
eISSN - 1473-5741
pISSN - 0959-4973
DOI - 10.1097/cad.0000000000001232
Subject(s) - medicine , pancreatic cancer , immunotherapy , oncology , chemotherapy , cancer , metastasis , survival rate , disease
Pancreatic cancer is digestive cancer with limited therapeutic options and a poor outcome. Pancreatic cancer has a high mortality rate, with a 5-year survival rate of less than 5%. The median survival after metastasis of the disease is less than 6 months. Studies have revealed that the standard treatment, including palliative chemotherapy or immunotherapy, is not significantly effective for pancreatic cancer. Herein, we report a case of pancreatic cancer who benefited from a combination of anti-PD-1 immunotherapy and chemotherapy.